Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics, Merck Form Research Collaboration

NEW YORK, Oct. 20 (GenomeWeb News) - Celera Diagnostics said today that it has formed a research collaboration with Rosetta Inpharmatics, and its parent company Merck, to identify and validate genetic markers that can be used to develop tests and treatments for select cancers.


Under the arrangement, Celera Diagnostics will ahve access to certain Rosetta gene expression data and intellectual property. Merck will have access to certain research data from Celera Diagnostics that can be applied toward cancer drug development.


The partnership is initally focused on breast cancer, but may be expanded to include other malignancies.  Additional terms of the deal were not disclosed.


"Celera Diagnostics has accessed two large collections of tissue samples to support its ongoing disease association studies in breast cancer," Tom White, CSO of Celera Diagnostics, said in a statement. "We believe our studies, coupled with Merck's groundbreaking work, could lead to prognostic tests suitable for routine clinical practice, as well as the identification of novel drug targets for cancer treatment."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.